A comparison of a prototype PCR assay and Hybrid Capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears

American Journal of Clinical Pathology

Volumn 124, Issue 5, 2005, Pages 722-732

  Schiffman, Mark ^a   Wheeler, Cosette M ^b   Dasgupta, Abhijit ^a   Solomon, Diane ^a   Castle, Philip E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Cervical intraepithelial neoplasia; HPV; Human papillomavirus; Hybrid Capture; PCR; Polymerase chain reaction; Triage

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER SCREENING; CARCINOGENESIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

EID: 24144497484     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/E067X0L1U3CY37NW     Document Type: Article

References (28)

1. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
2. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281:1605-1610.
3. Arbyn M, Buntinx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal Pap smears: a metaanalysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004;96:280-293.
4. Davey DD, Woodhouse S, Styer P, et al. Atypical epithelial cells and specimen adequacy: current laboratory practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2000;124:203-211.
5. Kinney WK, Manos MM, Hurley LB, et al. Where's the high-grade cervical neoplasia? the importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol. 1998;91:973-976.
6. Bosch FX, Manos MM, Munoz N, et al, for the International Biological Study on Cervical Cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;87:796-802.
7. Castle PE, Solomon D, Schiffman M, et al. HPV16 infection and the two-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005;97:1066-1071.
8. Stoler MH. HPV testing in cervical cytology practice: it's all about choice [editorial]. Acta Cytol. 2005;49:117-119.
9. Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study: design, methods and characteristics of trial participants. Acta Cytol. 2000;44:726-742.
10. Guido R, Schiffman M, Solomon D, et al. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol. 2003;188:1401-1405.
11. Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003;188:1406-1412.
12. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393-1400.
13. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383-1392.
14. Lorincz A, Anthony J. Advances in HPV detection by Hybrid Capture. Papillomavirus Rep. 2001;12:145-154.
15. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283:87-93.
16. Cogliano V, Baan R, Straif K, et al, and the WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.
17. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38:357-361.
18. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
19. Gravitt PE, Burk RD, Lorincz A, et al. A comparison between real-time polymerase chain reaction and Hybrid Capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev. 2003;12:477-484.
20. Castle PE, Schiffman M, Burk RD, et al. Restricted cross-reactivity of Hybrid Capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev. 2002;11:1394-1399.
21. Peyton CL, Schiffman M, Lorincz AT, et al. Comparison of PCR- and Hybrid Capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol. 1998;36:3248-3254.
22. Schiffman M, Khan MJ, Solomon D, et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005;97:147-150.
23. Sherman ME, Wang SS, Tarone R, et al. Histopathologic extent of cervical intraepithelial neoplasia 3 lesions in the Atypical Squamous Cells of Undetermined Significance Low-Grade Squamous Intraepithelial Lesion Triage Study: implications for subject safety and lead-time bias. Cancer Epidemiol Biomarkers Prev. 2003;12:372-379.
24. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500-1505.
25. Lefevre J, Hankins C, Pourreaux K, et al. Prevalence of selective inhibition of HPV-16 DNA amplification in cervicovaginal lavages. J Med Virol. 2004;72:132-137.
26. Castle PE, Wheeler CM, Solomon D, et al, for the ALTS Group. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol. 2004;122:238-245.
27. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med. 2003;348:489-490.
28. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288:1749-1757.